Scrip
Amgen's Vectibix yields mixed results in second-line Phase III colorectal cancer trial
18 August 2009
Malini Guha
Amgen's EGFR-targeted human monoclonal antibody, Vectibix (panitumumab), met one of its co-primary endpoints, progression-free survival (PFS), but not the other, overall survival, in patients with KRAS wild-type metastatic colorectal cancer (mCRC) in the pivotal Phase III "181" trial testing it as...
Please Login to read the full article.
18 August 2009
Malini Guha
Please Login to read the full article.
RELATED CONTENT
NEWS
- Amgen's Vectibix meets goal in pivotal first-line trial in colorectal cancer
- Amgen's Vectibix fails to show survival benefit in pivotal first-line trial in colorectal cancer
- Mixed Phase III results for Erbitux in first-line colorectal cancer
- Erbitux not recommended for EU approval in lung cancer
COMMENT
Other Informa Comment
EVENTS
11 March 2010
Cambridge, UK
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
